planned Phase
controlled safety studies
safety data
Prophylactic Ebola Vaccine
Filo vaccine
proposed vaccine
trials
translational studies
use
robust data
immunogenicity
ages
WP2
Ebola programme projects
immune responses
development program
capacity of African centres
protection
Heterologous Prime-Boost Regimen
vaccinated non-human primates
staff
humans
ZEBOV
children
Ad26
MVA-BN
special population groups
infrastructure
Central Information Repository
main objective
European volunteers
overall target enrolment
WP4
countries
years
preparation
efficacy
key stakeholders
wider community
subjects
compressed nature
study
EBOVAC1
HIV
results of EBOVAC2
WP6
WP5
individuals
elderly
WP3
placebo
locations